In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML- RARα/PML proteins

Blood

Volumn 88, Issue 3, 1996, Pages 1052-1061

  Chen, Guo Qiang ^b   Zhu, Jun ^b   Shi, Xue Geng ^b   Ni, Jian Hua ^b   Zhong, Hao Jie ^b   Si, Gui Ying ^b   Jin, Xiao Long ^b   Tang, Wei ^b   Li, Xiu Shong ^b   Xong, Shu Ming ^b   Shen, Zhi Xiang ^b   Sun, Guan Lin ^b   Ma, Jun ^b   Zhang, Peng ^b   Zhang, Ting Dong ^b   Gazin, Claude ^b   Naoe, Tomoki ^b   Chen, Sai Juan ^b   Wang, Zhen Yi ^b   Chen, Zhu ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; PROTEIN BCL 2; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0010740572     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.3.1052.bloodjournal8831052     Document Type: Article

References (52)

1. de The H, Chomienne C, Lanotte M, Degos L, Dejean A: The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 347:558, 1990
2. Tong JH, Dong S, Geng JP, Huang W, Wang ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ, Berger R: Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL,M3) define a breakpoint cluster region as well as some molecular variants. Oncogene 7:311, 1992
3. Degos L, Dombret H, Chomienne C, Daniel NT, Miclea JM, Chastang C, Castaigne S, Fenaux P: ATRA as a differentiation agent in the treatment of acute promyelocytic leukemia. Blood 85:2643, 1995
4. Warrell RP Jr, de The H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 329:177, 1993
5. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhao L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
6. Castaigne S, Chomienne C, Daniel M, Ballerini P, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. Blood 76:1704, 1990
7. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Nonti E, Biondi A, LoCoco F, Grignani F, Pelieci PG: Acute promyelocytic leukemia: From genetics to treatment. Blood 83:10, 1994
8. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr: The retinoic acid syndrome in acute promyelocytic leukemia. Ann Intern Med 117:292, 1992
9. Delva L, Comic M, Balitrand N, Guidez F, Miclea JM, Delmer A, Teillet F, Fenaux P, Castaigne S, Degos L, Chomienne C: Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro all-trans retinoic acid sensitivty and cellular retinoic acid-binding protein levels in leukemic cell. Blood 82:2175, 1993
10. Warrell RP Jr: Retinoid resistance in acute promyelocytic leukemia: New mechanisms, strategies and implications. Blood 82:1949, 1993
11. Sun HD, Ma L, Hu XC, Zhang TD: Ai-Lin I treated 32 cases of acute promyelocytic leukemia. Chin J Integrat of Chinese and Western Medicine 12:170, 1992
12. Huang SL, Guo AX, Xiang Y, Wang XB, HJ Ling, L Fu: Clinical study on the treatment of APL mainly with composite Indigo Naturalis tablets. Chin J Hematol 16:26, 1995
13. 4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia(M3). Blood 77:1081, 1991
14. Ormerod MG, Collins MK, Rodriguez-Tarduchy G, Robertson D: Apoptosis in interleukin-3-dependent hemopoietic cells. Quantification by two flow cytometric methods. J Immunol Methods 153:57, 1992
15. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609, 1993
16. Boise LH, Gonzalez-Garcia M, Postema CE, Ding LY, Lindsten T, Turka LA, Mao XH, Nunez G, Thompson CB: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597, 1993
17. Cleary ML, Smith SD, Asklar J: Cloning and structural analysis of cDNAs for bcl-2 and a bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 47:19, 1986
18. 4 Leukemia 9:302, 1995
19. Darzynkiewicz Z, Bruno S, Del Bino G: Features of apoptotic cells measured by flow cytometry. Cytometry 13:795, 1992
20. Bishop C, Kipling MD: Arsenic and cancer. J Soc Occup Med 28:3, 1978
21. Nielsen FH, Uthus EO: Arsenic, in Frieden E (ed): Biochemistry of the Essential Ultratrace Elements. New York. NY, Plenum, 1981, p 319
22. Dong JT, Luo XM: Effects of arsenic on DNA damage and repair in human fetal lung fibroblasts. Mutat Res 315:11, 1994
23. Lee TC, Oshimura M, Barrent JC: Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis 6:1421, 1985
24. Lerda D: Sister-chromatid exchange(SCE) among individuals chronically exposed to arsenic in drinking water. Mutat Res 312:111, 1994
25. Bergamaschi G, Rosti V, Danova M, Lucotti C. Cazzola M: Apoptosis: Biological and clinical aspects. Haematologica 79:86, 1994
26. Ellis RE, Yuan J, Horvitz HR: Mechanisms and functions of cell death. Annu Rev Cell Biol 7:663, 1991
27. Raff MC: Social controls on cell survival and cell death. Nature 356:397, 1992
28. Steller H: Mechanisms and genes of cellular suicide. Science 267:1445, 1995
29. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 267:1456, 1995
30. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539, 1994
31. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703, 1994
32. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukein-6. Nature 352:345, 1991
33. Shi Y, Glynn TM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR: Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257:212, 1992
34. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
35. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1, 1994
36. Hockembery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer S: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241, 1993
37. Yang E, Zha JP, Jockel J, Boise LH, Thompson CB, Korsmeyer: Bad, a heterodimeric partner for bcl-X, and bcl-2. displaces bax and promotes cell death. Cell 80:285, 1995
38. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: A novel bcl-2-binding protein with anti-cell death activity. Cell 80:279, 1995
39. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activitor of the human bax gene. Cell 80:293, 1995
40. Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin HK, Hoffman B, Lieberman D, Reed JC: Tumor supressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene 9:1799, 1994
41. Miyashita T, Harigai M, Hanada M, Reed JC: Identification of a p53-dependent negative response elemwent in the bcl-2 gene. Cancer Res 53:3331, 1994
42. Krajewski S, Krajewski M, Shabaik A, Miyashita T, Wang HG, Reed JC: Immunohistochemical determination of in vivo distribution of bax, adomonant inhibitor of bcl-2. Am J Pathol 145:1323, 1994
43. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise L, Thompson C, Golemis E, Fong L, Wang HG, Reed JC: Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system. Proc Natl Acad Sci USA 91:9238, 1994
44. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369:321, 1994
45. Bruel A, Benoit G, Nay D De, Brown S, Lanotte M. Distinct apoptotic responses in maturation sensitive and resistant t(15;17) acute promyelocytic leukemia NB4 cells. 9-cis retinoic acid induces apoptosis independent of maturation and bcl-2 expression. Leukemia 9:1173, 1995
46. Mu ZM, Chin KV, Liu JH, Lozano G, Chang KS: PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 14:6858, 1994
47. Chang KS, Fan YH, Andreff M, Lin J, Mu ZM: The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 85:3646, 1995
48. Koken MHM, Linares-Cruz G. Guignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, Juhlin L, Degos L, Calvo F, de The H: The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10:1315, 1995
49. Weis K, Rambaud S, Lavau C, Jansen JM, Carvalho T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell 76:345, 1994
50. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocytic-retinoic acid receptor oncoprotein. Cell 76:333, 1994
51. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, de Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H: The 1(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13:1073, 1994
52. Grignani FR, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I, Pellici PG: The acute promyelocytic leukemia specific PML/RARα protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423, 1993